Clinical Trial Update: A Phase 2 Study of Intravenous or Subcutaneous Dosing of Sotatercept (ACE-011) in Patients With End-Stage Kidney Disease on Hemodialysis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating intravenous or subcutaneous sotatercept (ACE-011) in patients with end-stage renal disease on hemodialysis has completed and posted res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• End-stage Renal Disease

Drugs mentioned

• Sotatercept (sotatercept)

Snippet

Sponsor: Celgene | Conditions: Anemia, Kidney Failure, Chronic | Phase 2 | Status: COMPLETED | Results posted: 2024-06-24